{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:39:02Z","timestamp":1765438742303,"version":"3.40.5"},"reference-count":24,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Kaohsiung J of Med Scie"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To investigate the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris (UA). The present prospective study included a total of 291 patients who were diagnosed as unstable UA from January 2018 to December 2019. All UA patients were divided into two groups: ticagrelor combined with tirofiban group (<jats:italic>n<\/jats:italic>\u00a0=\u00a0159) and clopidogrel combined with tirofiban group (<jats:italic>n<\/jats:italic>\u00a0=\u00a0132). Serum levels of C\u2010reactive protein (CRP), interleukin\u20101\u03b2, interleukin\u20106, tumor necrosis factor\u2010\u03b1, and matrix metalloproteinase\u20109 were measured using commercially available enzyme\u2010linked immunosorbent assay kits. Kaplan\u2013Meier (K\u2010M) curve was performed for analysis of cumulative incidences of major adverse cardiovascular events (MACEs). Both ticagrelor combined with tirofiban and clopidogrel combined with tirofiban significantly decreased the serum levels of inflammatory factors in UA patients. Compared to clopidogrel combined with the tirofiban group, ticagrelor combined with the tirofiban group had a lower platelet aggregation rate and improved cardiac function of UA patients. Besides, ticagrelor combined with tirofiban group had a better prognosis and the K\u2010M curve showed that UA patients treated by ticagrelor and tirofiban had lower incidences of MACEs in one\u2010year follow\u2010up. The treatment of ticagrelor combined with tirofiban significantly attenuated inflammation response and improved the prognosis of UA patients.<\/jats:p>","DOI":"10.1002\/kjm2.12421","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T12:30:11Z","timestamp":1627907411000},"page":"1010-1015","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow\u2010up"],"prefix":"10.1002","volume":"37","author":[{"given":"Li","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Pharmacy Tianyou Hospital Affiliated to Wuhan University of Science and Technology  Wuhan China"},{"name":"Hubei Province Key Laboratory of Occupational Hazard Identification and Control Wuhan University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai\u2010Zhen","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Tianyou Hospital Affiliated to Wuhan University of Science and Technology  Wuhan China"},{"name":"Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao\u2010Chun","family":"Li","sequence":"additional","affiliation":[{"name":"Hubei Province Key Laboratory of Occupational Hazard Identification and Control Wuhan University of Science and Technology  Wuhan China"},{"name":"Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1801-7367","authenticated-orcid":false,"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Hubei Province Key Laboratory of Occupational Hazard Identification and Control Wuhan University of Science and Technology  Wuhan China"},{"name":"Intensive Care Unit Tianyou Hospital Affiliated to Wuhan University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817083"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-19-0133"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916870"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7580"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.023"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.01.531"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz917"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.08.024"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-02-0180"},{"issue":"1","key":"e_1_2_8_11_1","first-page":"71","article-title":"Primary evaluation to safety and value in high risk strati\u2010ficated patients with ACS referred to Tirofiban therapy","volume":"28","author":"Han XG","year":"2007","journal-title":"J Tongji Univ (Med Sci)"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20424"},{"key":"e_1_2_8_13_1","first-page":"24","article-title":"AHA\/ACC guideline for theManagement of patients WithNon\u2013ST\u2010elevation acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association task force on practice guidelines \u2010 ScienceDirect","volume":"64","author":"NKW EAA","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"e_1_2_8_14_1","first-page":"e240","article-title":"American College of Cardiology Foundation; American Heart Association task force on practice guidelines. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"128","author":"Yancy CW","year":"2013","journal-title":"Circulation"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537101003768201"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2013.04.002"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02673.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25850"},{"issue":"4","key":"e_1_2_8_19_1","first-page":"702","article-title":"Onset of optimal P2Y12\u2010ADP receptor blockade after ticagrelor and prasugrel intake in non\u2010ST elevation acute coronary syndrome","volume":"114","author":"Bonello LLM","year":"2015","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2014.888410"},{"issue":"7","key":"e_1_2_8_21_1","first-page":"11360","article-title":"Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI)","volume":"8","author":"Liu Y","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2011.03.017"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.01.367"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22575"},{"issue":"4","key":"e_1_2_8_25_1","first-page":"3383","article-title":"Effects of tirofiban on stent thrombosis, Hs\u2010CRP, IL\u20106 and sICAM\u20101 after PCI of acute myocardial infarction","volume":"16","author":"Zhang Y","year":"2018","journal-title":"Exp Ther Med"}],"container-title":["The Kaohsiung Journal of Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/kjm2.12421","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/kjm2.12421","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/kjm2.12421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T12:08:05Z","timestamp":1693224485000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/kjm2.12421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/kjm2.12421"],"URL":"https:\/\/doi.org\/10.1002\/kjm2.12421","archive":["Portico"],"relation":{},"ISSN":["1607-551X","2410-8650"],"issn-type":[{"type":"print","value":"1607-551X"},{"type":"electronic","value":"2410-8650"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"2021-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}